CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.

EA Tivol, SD Boyd, S McKeon, F Borriello… - … (Baltimore, Md.: 1950 …, 1997 - journals.aai.org
EA Tivol, SD Boyd, S McKeon, F Borriello, P Nickerson, TB Strom, AH Sharpe
Journal of immunology (Baltimore, Md.: 1950), 1997journals.aai.org
Mice lacking CTLA-4 develop a fatal spontaneous lymphoproliferative disease with massive
lymphocytic infiltrates and tissue destruction in many organs. CTLA-4-deficient (-/-)
splenocytes and lymph node cells proliferate without added stimuli in vitro. We report here
that CTLA4Ig treatment of CTLA-4-/-mice prevents lymphoproliferation and fatal multiorgan
tissue damage in vivo and proliferation of CTLA-4-/-splenocytes and lymph node cells in
vitro. Therefore, stimulation via CD28-B7 interactions appears necessary for CTLA-4-/-T cell …
Abstract
Mice lacking CTLA-4 develop a fatal spontaneous lymphoproliferative disease with massive lymphocytic infiltrates and tissue destruction in many organs. CTLA-4-deficient (-/-) splenocytes and lymph node cells proliferate without added stimuli in vitro. We report here that CTLA4Ig treatment of CTLA-4 -/- mice prevents lymphoproliferation and fatal multiorgan tissue damage in vivo and proliferation of CTLA-4 -/- splenocytes and lymph node cells in vitro. Therefore, stimulation via CD28-B7 interactions appears necessary for CTLA-4 -/- T cell proliferation and the production of lymphoproliferative disease in vivo. When CTLA4Ig treatment is terminated, CTLA-4 -/- T cells become activated and lymphoproliferative disease develops. The lack of long term protective effects of CTLA4Ig treatment suggests that CTLA-4 is needed for the induction and or maintenance of tolerance.
journals.aai.org